Analysts Offer Insights on Healthcare Companies: Xeris Pharmaceuticals (XERS), Quanterix (QTRX) and Walgreens Boots Alliance (WBA)
Craig-Hallum Maintains Xeris Pharmaceuticals(XERS.US) With Buy Rating
Craig-Hallum Maintains Xeris Pharmaceuticals(XERS.US) With Buy Rating
Xeris Pharmaceuticals (XERS) Receives a Buy From Craig-Hallum
Craig-Hallum Maintains Xeris Pharmaceuticals(XERS.US) With Buy Rating, Announces Target Price $5
Xeris Biopharma Price Target Maintained With a $3.00/Share by Piper Sandler
Xeris Biopharma Holdings Analyst Ratings
H.C. Wainwright Maintains Xeris Pharmaceuticals(XERS.US) With Buy Rating, Raises Target Price to $6.6
Xeris Pharmaceuticals: Hold Rating Amid Growth and Cost Concerns
Craig-Hallum Maintains Xeris Pharmaceuticals(XERS.US) With Buy Rating
Craig-Hallum Maintains Xeris Pharmaceuticals(XERS.US) With Buy Rating
Craig-Hallum Maintains Xeris Pharmaceuticals(XERS.US) With Buy Rating
Craig-Hallum Maintains Xeris Pharmaceuticals(XERS.US) With Buy Rating
Craig-Hallum Maintains Xeris Pharmaceuticals(XERS.US) With Buy Rating
Xeris Pharmaceuticals (XERS) Gets a Buy From Craig-Hallum
Oppenheimer Maintains Xeris Pharmaceuticals(XERS.US) With Buy Rating, Maintains Target Price $5
Oppenheimer Remains a Buy on Xeris Pharmaceuticals (XERS)
HC Wainwright & Co. Reiterates Buy on Xeris Biopharma Holdings, Maintains $6 Price Target
Xeris Biopharma Holdings Analyst Ratings
H.C. Wainwright Maintains Xeris Pharmaceuticals(XERS.US) With Buy Rating, Maintains Target Price $6